search
Back to results

Plasma Trimethylamine N-oxide Elevation Induced by L-carnitine Supplementation and Insulin Resistance (MR)

Primary Purpose

Insulin Resistance

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
L-carnitine
L-leucine
Change of the circadian cycle
Sponsored by
Poznan University of Physical Education
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Insulin Resistance

Eligibility Criteria

20 Years - 30 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy volunteers,
  • must be able to swallow tablets

Exclusion Criteria:

  • smokers,
  • cardiovascular disease
  • liver disease
  • kidney disease
  • gastrointestinal disorders (including stomach ulcers and erosions)
  • diabetes

Sites / Locations

  • Akademia Wychowania Fizycznego

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Active Comparator

Arm Label

carnitine

leucine

modified circadian cycle

normal circadian cycle

Arm Description

2 grams of L-carnitine per day for 12 weeks

2 grams of L-leucine per day for 12 weeks

no sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00).

sleep at night for four consecutive days

Outcomes

Primary Outcome Measures

Circulating microbiome metabolites
Determination of plasma trimethylamine and trimethylamine N-oxide using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method
Circulating carnitine metabolites
Determination of plasma free, total, and acyl-L-carnitines using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method
Circulating diabetes biomarkers
insulin, C-peptide, ghrelin, leptin, resistin using enzyme-linked immunosorbent assay
Circulating inflammatory biomarkers
tumor necrosis factor, C-reactive protein using enzyme-linked immunosorbent assay
Oral Glucose Tolerance Test
The subjects will consume 75 g of glucose solution drink within a 5-minute time frame. The glucose level will be continuously monitored with the FreeStyle Libre Sensor.

Secondary Outcome Measures

gut microbiome composition
16 S rRNA sequencing will be used to analyze the gut microbiome in the stool samples

Full Information

First Posted
February 11, 2022
Last Updated
March 10, 2022
Sponsor
Poznan University of Physical Education
search

1. Study Identification

Unique Protocol Identification Number
NCT05251207
Brief Title
Plasma Trimethylamine N-oxide Elevation Induced by L-carnitine Supplementation and Insulin Resistance
Acronym
MR
Official Title
The Role of Gut Microbiota Metabolite, Trimethylamine N-oxide, in the Insulin Resistance Development
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
February 7, 2022 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
May 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Poznan University of Physical Education

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The primary aims of the current study: using L-carnitine supplementation modulate the level of plasma trimethylamine N-oxide to assess its effect on circulating cytokines related to diabetes and metabolic syndrome; using simulated night-shift work intervention as a stress factor, explore the effect of circulating metabolites on insulin sensitivity The secondary aim is to evaluate the effect of carnitine supplementation on gut microbiome composition.
Detailed Description
Subjects will be randomly divided in two groups: supplemented by L-carnitine 2g/day for 12 weeks, and placebo group receiving leucine in identical gelatine capsules. Subjects who successfully complete the protocol will be divided into four subgroups - two with a changed circadian cycle and two controls (supplemented and placebo). Subgroups with a changed daily cycle will be able to sleep between 8:00 and 17:00 for four consecutive days, while during the night they will stay active in the laboratory. The oral glucose tolerance test (OGTT) will be performed before and after the circadian cycle modification. Glucose levels will be monitored by FreeStyle Libre Sensor. Moreover, the activity of the participants will be monitored by wearable activity trackers. Before supplementation, as well as before circadian cycle modification and after finishing the whole experimental procedure, fasting blood samples will be collected for determination of plasma trimethylamine N-oxide (TMAO), trimethylamine (TMA), carnitine (free and acyl derivatives), protein markers of diabetes and inflammation. Moreover, the stool samples will be collected before and after 12 weeks of supplementation, to determine the composition of the gut microbiome. In addition diet of participants will be monitored.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
carnitine
Arm Type
Experimental
Arm Description
2 grams of L-carnitine per day for 12 weeks
Arm Title
leucine
Arm Type
Placebo Comparator
Arm Description
2 grams of L-leucine per day for 12 weeks
Arm Title
modified circadian cycle
Arm Type
Experimental
Arm Description
no sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00).
Arm Title
normal circadian cycle
Arm Type
Active Comparator
Arm Description
sleep at night for four consecutive days
Intervention Type
Dietary Supplement
Intervention Name(s)
L-carnitine
Intervention Description
L-carnitine-L-tartrate
Intervention Type
Dietary Supplement
Intervention Name(s)
L-leucine
Intervention Description
L-leucine
Intervention Type
Behavioral
Intervention Name(s)
Change of the circadian cycle
Intervention Description
Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
Primary Outcome Measure Information:
Title
Circulating microbiome metabolites
Description
Determination of plasma trimethylamine and trimethylamine N-oxide using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method
Time Frame
13 weeks
Title
Circulating carnitine metabolites
Description
Determination of plasma free, total, and acyl-L-carnitines using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method
Time Frame
13 weeks
Title
Circulating diabetes biomarkers
Description
insulin, C-peptide, ghrelin, leptin, resistin using enzyme-linked immunosorbent assay
Time Frame
13 weeks
Title
Circulating inflammatory biomarkers
Description
tumor necrosis factor, C-reactive protein using enzyme-linked immunosorbent assay
Time Frame
13 weeks
Title
Oral Glucose Tolerance Test
Description
The subjects will consume 75 g of glucose solution drink within a 5-minute time frame. The glucose level will be continuously monitored with the FreeStyle Libre Sensor.
Time Frame
1 week
Secondary Outcome Measure Information:
Title
gut microbiome composition
Description
16 S rRNA sequencing will be used to analyze the gut microbiome in the stool samples
Time Frame
13 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy volunteers, must be able to swallow tablets Exclusion Criteria: smokers, cardiovascular disease liver disease kidney disease gastrointestinal disorders (including stomach ulcers and erosions) diabetes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Olek, PhD
Organizational Affiliation
Poznan University of Physical Education
Official's Role
Principal Investigator
Facility Information:
Facility Name
Akademia Wychowania Fizycznego
City
Poznań
ZIP/Postal Code
61-871
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
30485835
Citation
Samulak JJ, Sawicka AK, Hartmane D, Grinberga S, Pugovics O, Lysiak-Szydlowska W, Olek RA. L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women. Ann Nutr Metab. 2019;74(1):11-17. doi: 10.1159/000495037. Epub 2018 Nov 28.
Results Reference
background
PubMed Identifier
29356345
Citation
Bescos R, Boden MJ, Jackson ML, Trewin AJ, Marin EC, Levinger I, Garnham A, Hiam DS, Falcao-Tebas F, Conte F, Owens JA, Kennaway DJ, McConell GK. Four days of simulated shift work reduces insulin sensitivity in humans. Acta Physiol (Oxf). 2018 Jun;223(2):e13039. doi: 10.1111/apha.13039. Epub 2018 Feb 12.
Results Reference
background

Learn more about this trial

Plasma Trimethylamine N-oxide Elevation Induced by L-carnitine Supplementation and Insulin Resistance

We'll reach out to this number within 24 hrs